DESIGN, SYNTHESIS AND CHARACTERISATION OF A NOVEL TYPE II B-RAF PARADOX BREAKER INHIBITOR - Université d'Orléans Accéder directement au contenu
Article Dans Une Revue European Journal of Medicinal Chemistry Année : 2023

DESIGN, SYNTHESIS AND CHARACTERISATION OF A NOVEL TYPE II B-RAF PARADOX BREAKER INHIBITOR

Résumé

The mutation V600E in B-Raf leads to MAPK pathway activation, uncontrolled cell proliferation, and tumorigenesis. ATP competitive type I B-Raf inhibitors, such as vemurafenib (1) and PLX4720 (4) efficiently block the MAPK pathways in B-Raf mutant cells, however these inhibitors induce conformational changes in the wild type B-Raf (wt B-Raf) kinase domain leading to heterodimerisation with C-Raf, causing paradoxical hyperactivation of the MAPK pathway. This unwanted activation may be avoided by another class of inhibitors (type II) which bind the kinase in the DFG-out conformation, such as AZ628 (3) preventing heterodimerization. Here we present a new B-Raf kinase domain inhibitor that represents a hybrid between 4 and 3. This novel inhibitor borrows the hinge binding region from 4 and the back pocket binding moiety from 3. We designed, synthesized, determined its binding mode, performed activity/selectivity studies, and molecular dynamics simulations in order to study the conformational effects induced by this inhibitor on wt and V600E mutant B-Raf kinase. We discovered that the inhibitor binds in a DFG-out/αC-helix-in conformation, did not induce the aforementioned paradoxical hyperactivation in the MAPK pathway, and it was active and highly selective for B-Raf. We propose that this merging approach can be used to design a novel class of B-Raf inhibitors for translational studies.
Fichier principal
Vignette du fichier
manuscript_final.pdf (1.27 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04037562 , version 1 (20-03-2023)

Identifiants

Citer

Rohit Arora, Joannes T.M. Linders, Samia Aci-Sèche, Thomas Verheyen, Erika van Heerde, et al.. DESIGN, SYNTHESIS AND CHARACTERISATION OF A NOVEL TYPE II B-RAF PARADOX BREAKER INHIBITOR. European Journal of Medicinal Chemistry, 2023, 250, pp.115231. ⟨10.1016/j.ejmech.2023.115231⟩. ⟨hal-04037562⟩
25 Consultations
35 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More